Xalacom Eye Drop is a combination ophthalmic solution containing Timolol 5 mg/ml and Latanoprost 50 mcg/ml, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Timolol, a non-selective beta-adrenergic receptor blocker, decreases aqueous humor production, thereby lowering IOP. Latanoprost, a prostaglandin F2α analogue, enhances uveoscleral outflow, contributing to further IOP reduction. The dual mechanism of action provides an additive effect, improving therapeutic efficacy compared to monotherapy with either agent alone. Xalacom is typically administered as one drop once daily in the affected eye(s), preferably in the evening. Caution is advised in patients with respiratory conditions such as asthma or chronic obstructive pulmonary disease, bradycardia, heart block, or heart failure due to the systemic absorption of Timolol. Potential adverse effects include ocular irritation, conjunctival hyperemia, blurred vision, and changes in iris pigmentation. Patients should be monitored regularly for intraocular pressure response and adverse reactions. Xalacom Eye Drop offers a convenient and effective option for patients requiring combination therapy for glaucoma management, aiming to prevent optic nerve damage and preserve visual function.